Subscribe To

Price Alert Latest News Economic Calendar News

CODX / Co-Diagnostics says it CoSara JV wins clearance in India for Saragene Dengue and Chikungunya Multiplex Test

Co-Diagnostics Inc., revealed that CoSara Diagnostics Pvt Ltd., its joint venture for manufacturing and sales in India, has received clearance from the Central Drugs Standard Control Organization (CDSCO) in India to manufacture and sell its Saragene Dengue and Chikungunya Multiplex RT-PCR test as an in vitro diagnostic (IVD). Read More

Demo Live Account See Partner Details

Content Topics

Co

Diagnostics

Says

Cosara

Wins

Clearance

India

Saragene

Co diagnostics

Dengue

Chikungunya

Multiplex

Stock

CODX

Posted: Oct 6 2021, 12:13

Author Name: Proactive Investors

CODX News

By Zacks Investment Research
August 10, 2023

Co-Diagnostics, Inc. (CODX) Reports Q2 Loss, Lags Revenue Estimates

Co-Diagnostics, Inc. (CODX) came out with a quarterly loss of $0.31 per share versus the Zacks Consensus Estimate of a loss of $0.24. This compares to

By PRNewsWire
July 27, 2023

Co-Diagnostics, Inc. Announces Second Quarter 2023 Earnings Release Date and Webcast

SALT LAKE CITY , July 27, 2023 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ: CODX), a molecular diagnostics company with a unique, patented platform f

By Seeking Alpha
May 11, 2023

Co-Diagnostics, Inc. (CODX) Q1 2023 Earnings Call Transcript

Co-Diagnostics, Inc. (NASDAQ:CODX ) Q1 2023 Earnings Conference Call May 11, 2023 4:30 PM ET Company Participants Andrew Benson - Head, Investor Relat

By Zacks Investment Research
May 11, 2023

Co-Diagnostics, Inc. (CODX) Reports Q1 Loss, Lags Revenue Estimates

Co-Diagnostics, Inc. (CODX) came out with a quarterly loss of $0.20 per share versus the Zacks Consensus Estimate of a loss of $0.23. This compares to

By Zacks Investment Research
March 16, 2023

Co-Diagnostics, Inc. (CODX) Reports Q4 Loss, Misses Revenue Estimates

Co-Diagnostics, Inc. (CODX) delivered earnings and revenue surprises of -113.33% and 74.53%, respectively, for the quarter ended December 2022. Do the

By Seeking Alpha
March 16, 2023

Co-Diagnostics, Inc. (CODX) Q4 2022 Earnings Call Transcript

Co-Diagnostics, Inc. (NASDAQ:CODX ) Q4 2022 Earnings Conference Call March 16, 2023 4:30 PM ET Company Participants Andrew Benson - Head of Investor R

By PRNewsWire
March 9, 2023

CO-DIAGNOSTICS, INC. ANNOUNCES FOURTH QUARTER AND FULL YEAR 2022 EARNINGS RELEASE DATE AND WEBCAST

SALT LAKE CITY , March 9, 2023 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, patented platform f

By Proactive Investors
November 11, 2022

Co-Diagnostics ends 3Q with $86.5M in cash; makes significant progress on its Co-Dx PCR Home platform

Co-Diagnostics Inc (NASDAQ:CODX) posted financial results for the third quarter that revealed ample cash on hand, giving the company scope to further

Risk Disclosure:

Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
We would like to remind you that the data contained in this website is not necessarily real-time nor accurate.
The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. We and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of us and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. We may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.